Peptide Tier List 2026 S → F · 237 peptides
Every peptide on the site, ranked. A holistic editorial verdict that combines evidence strength, human data, effect magnitude, and real-world adoption.
How we rank
Tier is not the same as evidence level. Evidence level is mechanical — it measures how much research exists. Tier is the harder editorial call: it combines that evidence with effect size, the depth of human data specifically, safety footprint, and how consistently real-world use mirrors the trial outcomes. A peptide can have moderate evidence and still land at A-tier if the human signal is unambiguous and the effect is clinically meaningful. Another can have a stack of preclinical papers and stall at C because nothing translates.
S means established with overwhelming human data — typically FDA-approved or in late-stage trials with reproducible large effects. A means strong with a clear, reproducible effect. B is promising but not yet decisive. C is mixed or early. D is preliminary, mostly preclinical. F is below grade — kept on the list for completeness, not endorsement. This is editorial judgment, not clinical advice; consult a clinician before acting on anything here. Browse the full directory at /peptides.
Within a tier, peptides are ordered by popularity. Hover any peptide for details; click to open the full profile.
Reserved for peptides with multiple human randomized trials, a clearly demonstrated effect that replicates across studies, and broad real-world adoption — typically with FDA approval or extensive off-label clinical use. These are the peptides where the evidence is overwhelming and the effect size is hard to argue with.
Strong human data with a clear, reproducible effect. Either approved abroad, in late-stage trials, or with such consistent published support that the mechanism and outcome are well-mapped. Real-world adoption is solid; the open questions are dose optimization and long-term safety, not whether the thing works.
Promising. Some human data, often a phase II or open-label study, paired with consistent preclinical work. The signal is real but the effect size or duration is less certain than tier A. Most peptides at this grade are watched with cautious optimism — they may climb to A as more data lands.
Mixed. Early human data exists but the effect is inconsistent, or the trials are small / underpowered. Mechanism is plausible. Real-world reports vary widely. These are reasonable candidates to follow if you have a specific use case the research touches on, but the evidence is not yet decisive.
Preliminary. Mostly animal and mechanistic work, with little to no controlled human evidence. People discuss them based on theory or anecdote. We list them because they are part of the conversation, not because the data supports broad use.
Below grade. Either the evidence is essentially absent, the proposed effect doesn't replicate, or the marketing has run far ahead of the science. We keep these listed for completeness and so visitors can see why they don't belong on a serious shortlist.
See something you'd rank differently? The tier list reflects our reading of the literature as of 2026 and will move as new data is published. Each peptide page links to the underlying citations so you can audit the call. For the mechanical evidence-level dimension, see our evidence rubric.